Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

NCT03895372 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03895372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03895372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2019
Completion date
November 26, 2020
Enrollment
179 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis